PMID- 35417606
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220701
IS  - 1386-6346 (Print)
IS  - 1386-6346 (Linking)
VI  - 52
IP  - 7
DP  - 2022 Jul
TI  - Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy 
      and safety as primary systemic chemotherapy for hepatocellular carcinoma.
PG  - 630-640
LID - 10.1111/hepr.13771 [doi]
AB  - AIM: Atezolizumab plus bevacizumab and lenvatinib have each shown efficacy as 
      primary systemic chemotherapies for hepatocellular carcinoma (HCC) in clinical 
      trials. However, comparative trials of these two treatments have not been 
      conducted. This study aimed to compare the therapeutic outcomes of these two 
      treatments. METHODS: This prospectively registered multicenter study analyzed 272 
      patients with HCC who received atezolizumab plus bevacizumab (the Atezo + Beva 
      group; n = 90) or lenvatinib (the Len group; n = 182) as primary systemic 
      chemotherapy. After propensity score matching (PSM), 66 patients were assigned to 
      each group. RESULTS: After PSM, the median progression-free survival (PFS) was 
      significantly longer in the Atezo + Beva group than in the Len group (8.8 vs. 
      5.2 months; p = 0.012). No significant differences were noted between the two 
      groups in terms of median overall survival (not reached vs. 20.6 months; 
      p = 0.577), objective response rates (43.8% vs. 52.4%; p = 0.330), and disease 
      control rates (76.6% vs. 82.5%; p = 0.404). The percentage of patients with 
      modified albumin-bilirubin grades of one or 2a was maintained during treatment in 
      the Atezo + Beva group but decreased over time in the Len group. The rate of 
      discontinuation due to adverse events (AEs) was lower in the Atezo + Beva group 
      than in the Len group (12.1% vs. 28.8%; p = 0.018). CONCLUSIONS: Atezolizumab 
      plus bevacizumab showed prolonged PFS, maintained hepatic reserve, and had lower 
      rates of severe AEs compared with that on using lenvatinib as primary systemic 
      chemotherapy for HCC.
CI  - (c) 2022 Japan Society of Hepatology.
FAU - Maesaka, Kazuki
AU  - Maesaka K
AD  - Department of Gastroenterology and Hepatology, Osaka University Graduate School 
      of Medicine, Suita, Osaka, Japan.
FAU - Sakamori, Ryotaro
AU  - Sakamori R
AUID- ORCID: 0000-0002-1580-607X
AD  - Department of Gastroenterology and Hepatology, Osaka University Graduate School 
      of Medicine, Suita, Osaka, Japan.
FAU - Yamada, Ryoko
AU  - Yamada R
AD  - Department of Gastroenterology and Hepatology, Osaka University Graduate School 
      of Medicine, Suita, Osaka, Japan.
FAU - Doi, Akira
AU  - Doi A
AD  - Department of Gastroenterology and Hepatology, Osaka University Graduate School 
      of Medicine, Suita, Osaka, Japan.
FAU - Tahata, Yuki
AU  - Tahata Y
AD  - Department of Gastroenterology and Hepatology, Osaka University Graduate School 
      of Medicine, Suita, Osaka, Japan.
FAU - Miyazaki, Masanori
AU  - Miyazaki M
AD  - Department of Gastroenterology and Hepatology, Osaka Police Hospital, Osaka, 
      Osaka, Japan.
FAU - Ohkawa, Kazuyoshi
AU  - Ohkawa K
AUID- ORCID: 0000-0001-9700-2472
AD  - Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer 
      Institute, Osaka, Osaka, Japan.
FAU - Mita, Eiji
AU  - Mita E
AD  - Department of Gastroenterology and Hepatology, National Hospital Organization 
      Osaka National Hospital, Osaka, Osaka, Japan.
FAU - Iio, Sadaharu
AU  - Iio S
AD  - Department of Gastroenterology and Hepatology, Hyogo Prefectural Nishinomiya 
      Hospital, Nishinomiya, Hyogo, Japan.
FAU - Nozaki, Yasutoshi
AU  - Nozaki Y
AD  - Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, 
      Hyogo, Japan.
FAU - Yakushijin, Takayuki
AU  - Yakushijin T
AD  - Department of Gastroenterology and Hepatology, Osaka General Medical Center, 
      Osaka, Osaka, Japan.
FAU - Imai, Yasuharu
AU  - Imai Y
AD  - Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Ikeda, 
      Osaka, Japan.
FAU - Kodama, Takahiro
AU  - Kodama T
AUID- ORCID: 0000-0002-6250-1324
AD  - Department of Gastroenterology and Hepatology, Osaka University Graduate School 
      of Medicine, Suita, Osaka, Japan.
FAU - Hikita, Hayato
AU  - Hikita H
AUID- ORCID: 0000-0003-2488-7315
AD  - Department of Gastroenterology and Hepatology, Osaka University Graduate School 
      of Medicine, Suita, Osaka, Japan.
FAU - Tatsumi, Tomohide
AU  - Tatsumi T
AD  - Department of Gastroenterology and Hepatology, Osaka University Graduate School 
      of Medicine, Suita, Osaka, Japan.
FAU - Takehara, Tetsuo
AU  - Takehara T
AUID- ORCID: 0000-0001-5036-3457
AD  - Department of Gastroenterology and Hepatology, Osaka University Graduate School 
      of Medicine, Suita, Osaka, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220425
PL  - Netherlands
TA  - Hepatol Res
JT  - Hepatology research : the official journal of the Japan Society of Hepatology
JID - 9711801
OTO - NOTNLM
OT  - atezolizumab plus bevacizumab
OT  - hepatocellular carcinoma
OT  - lenvatinib
EDAT- 2022/04/14 06:00
MHDA- 2022/04/14 06:01
CRDT- 2022/04/13 17:13
PHST- 2022/03/08 00:00 [revised]
PHST- 2022/01/06 00:00 [received]
PHST- 2022/04/05 00:00 [accepted]
PHST- 2022/04/14 06:00 [pubmed]
PHST- 2022/04/14 06:01 [medline]
PHST- 2022/04/13 17:13 [entrez]
AID - 10.1111/hepr.13771 [doi]
PST - ppublish
SO  - Hepatol Res. 2022 Jul;52(7):630-640. doi: 10.1111/hepr.13771. Epub 2022 Apr 25.